RAPT Therapeutics Inc (RAPT) - Net Assets
Based on the latest financial reports, RAPT Therapeutics Inc (RAPT) has net assets worth $151.98 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($165.74 Million) and total liabilities ($13.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check RAPT Therapeutics Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $151.98 Million |
| % of Total Assets | 91.7% |
| Annual Growth Rate | N/A |
| 5-Year Change | 82.29% |
| 10-Year Change | N/A |
| Growth Volatility | 35.61 |
RAPT Therapeutics Inc - Net Assets Trend (2017–2024)
This chart illustrates how RAPT Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of RAPT Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for RAPT Therapeutics Inc (2017–2024)
The table below shows the annual net assets of RAPT Therapeutics Inc from 2017 to 2024. For live valuation and market cap data, see RAPT Therapeutics Inc (RAPT) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $189.90 Million | +29.16% |
| 2023-12-31 | $147.03 Million | -40.03% |
| 2022-12-31 | $245.17 Million | +31.54% |
| 2021-12-31 | $186.38 Million | +78.90% |
| 2020-12-31 | $104.18 Million | +42.47% |
| 2019-12-31 | $73.12 Million | +14.26% |
| 2018-12-31 | $64.00 Million | +202.55% |
| 2017-12-31 | $-62.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to RAPT Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 53174100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.00K | 0.01% |
| Other Comprehensive Income | $50.00K | 0.03% |
| Other Components | $804.39 Million | 423.58% |
| Total Equity | $189.90 Million | 100.00% |
RAPT Therapeutics Inc Competitors by Market Cap
The table below lists competitors of RAPT Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing Caishikou Department Store Co Ltd
SHG:605599
|
$1.68 Billion |
|
Wuxi Best Precision Machinery Co Ltd
SHE:300580
|
$1.68 Billion |
|
TBO Tek Ltd
NSE:TBOTEK
|
$1.68 Billion |
|
PC Connection Inc
NASDAQ:CNXN
|
$1.68 Billion |
|
Natco Pharma Limited
NSE:NATCOPHARM
|
$1.68 Billion |
|
Greatech Technology Bhd
KLSE:0208
|
$1.68 Billion |
|
Okeanis Eco Tankers Corp.
NYSE:ECO
|
$1.68 Billion |
|
German American Bancorp Inc
NASDAQ:GABC
|
$1.68 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RAPT Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 147,035,000 to 189,904,000, a change of 42,869,000 (29.2%).
- Net loss of 129,865,000 reduced equity.
- New share issuances of 152,007,000 increased equity.
- Other comprehensive income decreased equity by 53,000.
- Other factors increased equity by 20,780,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-129.87 Million | -68.38% |
| Share Issuances | $152.01 Million | +80.04% |
| Other Comprehensive Income | $-53.00K | -0.03% |
| Other Changes | $20.78 Million | +10.94% |
| Total Change | $- | 29.16% |
Book Value vs Market Value Analysis
This analysis compares RAPT Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.56x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-23.46 | $58.01 | x |
| 2018-12-31 | $24.06 | $58.01 | x |
| 2019-12-31 | $26.79 | $58.01 | x |
| 2020-12-31 | $34.53 | $58.01 | x |
| 2021-12-31 | $54.44 | $58.01 | x |
| 2022-12-31 | $60.27 | $58.01 | x |
| 2023-12-31 | $30.68 | $58.01 | x |
| 2024-12-31 | $37.27 | $58.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RAPT Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -68.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.27x
- Recent ROE (-68.38%) is below the historical average (-47.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.87 Million |
| 2018 | -56.48% | 0.00% | 0.00x | 1.09x | $-42.55 Million |
| 2019 | -58.80% | -4598.61% | 0.01x | 1.16x | $-50.31 Million |
| 2020 | -50.77% | -1049.03% | 0.04x | 1.14x | $-63.31 Million |
| 2021 | -36.60% | -1788.83% | 0.02x | 1.07x | $-86.85 Million |
| 2022 | -33.40% | -5362.21% | 0.01x | 1.09x | $-106.40 Million |
| 2023 | -79.44% | 0.00% | 0.00x | 1.18x | $-131.50 Million |
| 2024 | -68.38% | 0.00% | 0.00x | 1.27x | $-148.86 Million |
Industry Comparison
This section compares RAPT Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RAPT Therapeutics Inc (RAPT) | $151.98 Million | 0.00% | 0.09x | $1.68 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) an… Read more